<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Congenital rubella</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Congenital rubella</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Congenital rubella</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Antonio C Arrieta, MD, FIDSA, FPIDS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Congenital rubella infection (CRI) will be reviewed here. The epidemiology of rubella infection and issues related to rubella in pregnancy, including risk of rubella-associated congenital defects, are discussed separately. (See  <a class="medical medical_review" href="/d/html/8301.html" rel="external">"Rubella"</a> and  <a class="medical medical_review" href="/d/html/8312.html" rel="external">"Rubella in pregnancy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>The terms congenital rubella infection and congenital rubella syndrome are used throughout this topic:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital rubella infection (CRI)</strong> –CRI is the broader term, encompassing the full spectrum of outcomes from intrauterine rubella infection, ranging from miscarriage or stillbirth, to combinations of birth defects (ie, congenital rubella syndrome), to asymptomatic infection [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital rubella syndrome (CRS)</strong> –CRS is a subcategory of CRI that refers to variable constellations of birth defects (eg, sensorineural hearing loss [SNHL], congenital heart disease, cataracts, congenital glaucoma)  (<a class="graphic graphic_table graphicRef55913" href="/d/graphic/55913.html" rel="external">table 1</a>) [<a href="#rid1">1</a>].</p><p></p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Rubella virus is an important cause of vaccine-preventable birth defects and can cause epidemics. The epidemiology of congenital rubella infection (CRI) and congenital rubella syndrome (CRS) is generally similar to the epidemiology of rubella infection in pregnancy, which is discussed separately. (See  <a class="medical medical_review" href="/d/html/8312.html" rel="external">"Rubella in pregnancy", section on 'Epidemiology'</a>.)</p><p>CRS is rare in countries with established rubella immunization programs [<a href="#rid2">2-5</a>]. A single dose of rubella-containing vaccine (RCV) can provide lifelong protection against rubella. (See  <a class="medical medical_review" href="/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents"</a>.)</p><p>As of 2015, rubella has been eliminated from the entire Americas region [<a href="#rid5">5,6</a>]. In the United States, there have been fewer than 10 people reported as having rubella each year since 2012; all cases had evidence that they were infected when they were living or traveling outside of the United States [<a href="#rid7">7</a>]. </p><p>In other parts of the world, rubella control is accelerating through widespread implementation of vaccine programs. Among the 194 World Health Organization member states, the number with RCV in their routine immunization schedules increased from 132 (68 percent) in 2012 to 173 (89 percent) in 2020. In 2020, 70 percent of the world's infants were vaccinated against rubella [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/8301.html" rel="external">"Rubella", section on 'Burden of disease'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Maternal-fetal transmission of rubella virus occurs via hematogenous spread during maternal viremia, which usually occurs five to seven days after maternal inoculation. After infecting the placenta, the virus spreads through the vascular system of the developing fetus. The resulting congenital defects stem from cytopathic damage to blood vessels and ischemia in affected organs [<a href="#rid8">8-11</a>]. Fetal infection is chronic, persisting throughout gestation and after birth.</p><p>The risk of maternal-fetal transmission varies depending upon the time of maternal infection, with the highest risk in the first 10 weeks of gestation. The clinical manifestations also vary depending upon the time of maternal infection. Structural cardiac and eye defects typically result when maternal infection occurs before eight weeks, whereas hearing loss may be observed in maternal infections until 18 weeks gestation [<a href="#rid12">12,13</a>]. Congenital defects are unlikely if maternal infection occurs after 18 to 20 weeks gestation. (See  <a class="medical medical_review" href="/d/html/8312.html" rel="external">"Rubella in pregnancy", section on 'Congenital rubella syndrome'</a>.)</p><p>There are two proposed mechanisms for rubella cytopathology:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Virus-induced inhibition of cell division</strong> – Support for virus-induced inhibition of cell division is provided by observations that organs of congenitally infected infants are smaller and contain fewer cells than those of uninfected infants [<a href="#rid14">14</a>], mitotic activity is depressed in congenitally infected embryonic primary cell cultures [<a href="#rid10">10</a>], cell division is slowed in human fetal cells and BHK-21 cells that have been infected with rubella virus in vitro [<a href="#rid15">15-17</a>], and a protein extracted from rubella virus-infected human fetal cells inhibits mitosis in uninfected cells [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Direct cytopathic effects</strong> – Support for direct cytopathic effects is provided by an in vitro study demonstrating variable degrees of rubella virus-induced programmed cell death (apoptosis) in different cell lines [<a href="#rid19">19</a>]. These findings suggest that programmed cell death depends upon unique cellular properties and may provide an explanation for selective organ damage in congenital rubella syndrome (CRS). Subsequent studies demonstrating cell-specific rubella virus-induced apoptosis (in chorionic villi explants, monolayers of cytotrophoblasts, and adult lung fibroblasts but not in primary human fetal fibroblasts) may help to explain the persistence of virus in CRS [<a href="#rid20">20,21</a>].</p><p></p><p>Other possible explanations for the persistence of rubella virus in CRS include defects in cell-mediated immunity and selective immune tolerance to the rubella virus E1 protein [<a href="#rid22">22-24</a>].</p><p class="headingAnchor" id="H5"><span class="h1">IMMUNOLOGIC RESPONSE</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Humoral response</strong> – During the first 16 to 20 weeks of gestation, only 5 to 10 percent of maternal immunoglobulin G (IgG) rubella antibody is passively transferred to the fetus. The fetus's own immunoglobulin M (IgM), IgG, and immunoglobulin A (IgA) appear at 9 to 11 weeks of gestation, but circulating fetal antibody levels remain low. Fetal antibody levels increase at mid-gestation, with predominance of IgM. At the time of delivery, IgG predominates and is mainly of maternal origin; IgM levels are lower but entirely of fetal origin [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">After birth, the infant's IgM increases while maternally derived IgG decreases. In infants with congenital rubella infection (CRI), rubella-specific IgM generally persists for at least six months, often persisting for up to one year, and occasionally persisting for up to two years [<a href="#rid26">26</a>]. High levels of infant rubella-specific IgG antibody usually are sustained for several years after detectable rubella virus excretion ends. Over time, rubella-specific antibody levels decrease [<a href="#rid26">26</a>]; in 10 to 20 percent of patients, they may become undetectable [<a href="#rid27">27-30</a>].</p><p></p><p class="bulletIndent1">Some patients with CRI have a relative hypergammaglobulinemia (particularly of IgM and IgG) during the first few years of life, which results from the increased antigenic stimulus accompanying chronic infection [<a href="#rid31">31</a>]. There are few case reports of hypogammaglobulinemia following intrauterine rubella infection, which usually affects only IgA but may involve IgG, IgM, and IgA [<a href="#rid31">31,32</a>]. Alternatively, IgG may be decreased and IgM increased (two to three times normal adult levels) with or without abnormalities in IgA [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lack of booster response</strong> – Children with CRI whose rubella-specific antibody titers have decreased to an undetectable level do not develop a boost in antibody titer after rubella vaccination [<a href="#rid28">28,33</a>]. This may reflect immunologic tolerance following intrauterine exposure to rubella virus. The mechanism of immune tolerance is not known but may be related to selective tolerance to the rubella virus E1 protein or the immaturity of the fetal immune system during the first trimester of gestation [<a href="#rid24">24,34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cellular response</strong> – Defects in cell-mediated immunity and persistent T cell abnormalities have been reported in patients with CRI, particularly when infection occurs early in gestation [<a href="#rid23">23,35-38</a>]. Delayed-type hypersensitivity reactions, lymphocyte-mediated cytotoxicity, phytohemagglutinin-induced lymphocyte transformation, and interferon production are decreased compared with responses in individuals with postnatal rubella infection. T cell abnormalities may predispose patients with CRI to develop organ-specific autoimmunity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Possible role in autoimmunity</strong> – CRI is associated with increased risk for type 1 diabetes mellitus and thyroid disease (see <a class="local">'Late manifestations'</a> below). Patients with CRI have a high prevalence of pancreatic islet cell surface antibodies and antithyroid antibodies, suggesting that immune-mediated mechanisms may play a role in the development of diabetes and thyroid disease. However, there is no clear evidence that congenital rubella predisposes to subsequent autoimmunity. Approximately 20 percent of patients with congenital rubella syndrome (CRS) have pancreatic islet cell surface antibodies, but pancreatic islet cell antibodies (which are more closely related to immune-mediated diabetes) have not been detected [<a href="#rid39">39-41</a>]. This suggests that other factors, such as human leukocyte antigen type, are also important in the development of type 1 diabetes in patients with CRI [<a href="#rid39">39,40,42-45</a>]. (See  <a class="medical medical_review" href="/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus"</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H9"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Congenital rubella infection (CRI) may lead to fetal death in utero, preterm delivery, or congenital defects [<a href="#rid1">1</a>]. CRI is a chronic infection and has a broad spectrum of clinical manifestations that may manifest throughout life  (<a class="graphic graphic_table graphicRef75721" href="/d/graphic/75721.html" rel="external">table 2</a>) [<a href="#rid1">1,46</a>].</p><p>Deafness, cataracts  (<a class="graphic graphic_picture graphicRef64979" href="/d/graphic/64979.html" rel="external">picture 1</a>), and cardiac disease are the classic manifestations of congenital rubella syndrome (CRS) [<a href="#rid47">47,48</a>]. However, rubella virus may infect virtually every fetal organ [<a href="#rid31">31</a>]. Once CRI is established, it can persist for long periods.</p><p>The manifestations of CRI vary depending upon the timing of maternal infection. The incidence of defects may be as high as 80 to 85 percent if maternal rubella is acquired during the first trimester [<a href="#rid12">12,27,49</a>]. Little, if any, risk of congenital defects is associated with infection after 18 to 20 weeks gestation [<a href="#rid12">12,50</a>]; fetal growth restriction may be the only sequela of third-trimester infection [<a href="#rid27">27,51-53</a>]. (See  <a class="medical medical_review" href="/d/html/8312.html" rel="external">"Rubella in pregnancy", section on 'Congenital rubella syndrome'</a>.)</p><p>The case definition for CRS is summarized in the table and discussed below  (<a class="graphic graphic_table graphicRef55913" href="/d/graphic/55913.html" rel="external">table 1</a>). (See <a class="local">'Case definition'</a> below.)</p><p class="headingAnchor" id="H10"><span class="h2">Early manifestations</span><span class="headingEndMark"> — </span>The majority of infants with CRI are asymptomatic at birth but develop manifestations over time  (<a class="graphic graphic_table graphicRef75721" href="/d/graphic/75721.html" rel="external">table 2</a>) [<a href="#rid54">54-57</a>]. However, severe symptomatic neonatal infection can occur.</p><p>Early manifestations may include  (<a class="graphic graphic_table graphicRef75721" href="/d/graphic/75721.html" rel="external">table 2</a>) [<a href="#rid13">13,22,49,58,59</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fetal growth restriction</strong> – (See  <a class="medical medical_review" href="/d/html/5062.html" rel="external">"Infants with fetal (intrauterine) growth restriction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sensorineural hearing loss (SNHL)</strong> – Nearly two-thirds of children with CRI have SNHL, which is usually bilateral [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/6297.html" rel="external">"Hearing loss in children: Screening and evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central nervous system (CNS) involvement</strong> – CNS abnormalities may include meningoencephalitis, large anterior fontanelle, microcephaly, developmental delay, motor delay, and behavioral disorders [<a href="#rid13">13,31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital heart disease</strong> – Approximately one-half of children infected in early gestation have congenital heart disease [<a href="#rid1">1</a>]. Patent ductus arteriosus and branch pulmonary artery stenosis are the most common lesions [<a href="#rid60">60</a>]. Other reported lesions include pulmonary valvular stenosis, aortic stenosis, ventricular septal defect, tetralogy of Fallot, and coarctation of the aorta [<a href="#rid46">46,60</a>]. Stenosis of other vessels may be related to coronary, cerebral, renal, and peripheral vascular disease during adulthood [<a href="#rid61">61,62</a>]. (See  <a class="medical medical_review" href="/d/html/1421.html" rel="external">"Clinical manifestations and diagnosis of patent ductus arteriosus (PDA) in term infants, children, and adults"</a> and  <a class="medical medical_review" href="/d/html/5775.html" rel="external">"Valvar aortic stenosis in children"</a> and  <a class="medical medical_review" href="/d/html/5769.html" rel="external">"Tetralogy of Fallot (TOF): Pathophysiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eye disease</strong> – Findings may include cloudy cornea, cataract  (<a class="graphic graphic_picture graphicRef64979" href="/d/graphic/64979.html" rel="external">picture 1</a>), infantile glaucoma, and/or retinopathy  (<a class="graphic graphic_picture graphicRef70003" href="/d/graphic/70003.html" rel="external">picture 2</a>). Cataracts occur in approximately one-quarter of infants with CRS; infantile glaucoma is less common [<a href="#rid1">1</a>]. Cataracts and infantile glaucoma usually become apparent during the early weeks of life. "Salt and pepper" retinopathy  (<a class="graphic graphic_picture graphicRef70003" href="/d/graphic/70003.html" rel="external">picture 2</a>) is caused by disturbed growth of the pigmentary layer of the retina [<a href="#rid13">13,31</a>]. (See  <a class="medical medical_review" href="/d/html/6270.html" rel="external">"Cataract in children"</a> and  <a class="medical medical_review" href="/d/html/6272.html" rel="external">"Overview of glaucoma in infants and children", section on 'Secondary glaucoma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Other findings that can be seen in the newborn include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Petechiae and purpura ("blueberry muffin lesions")  (<a class="graphic graphic_picture graphicRef69581" href="/d/graphic/69581.html" rel="external">picture 3</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Thrombocytopenia</p><p class="bulletIndent2"><span class="glyph">•</span>Hemolytic anemia</p><p class="bulletIndent2"><span class="glyph">•</span>Hepatosplenomegaly, jaundice, hepatitis</p><p class="bulletIndent2"><span class="glyph">•</span>Diarrhea</p><p class="bulletIndent2"><span class="glyph">•</span>Interstitial pneumonia</p><p class="bulletIndent2"><span class="glyph">•</span>Myocarditis</p><p class="bulletIndent2"><span class="glyph">•</span>Radiolucent bone lesions (in the long bones)</p><p class="bulletIndent2"><span class="glyph">•</span>Lymphadenopathy</p><p></p><p class="bulletIndent1">Many of these neonatal manifestations are transient and not necessarily specific for CRI [<a href="#rid31">31</a>]. They typically clear spontaneously over days or weeks.</p><p></p><p class="bulletIndent1">The early manifestations have important prognostic implications. The risk of mortality is increased in neonates with severe defects (eg, very low birth weight, extreme prematurity, extensive meningoencephalitis, gross cardiac lesions or myocarditis with early heart failure, fulminant interstitial pneumonitis, and rapidly progressive hepatitis) [<a href="#rid13">13</a>].</p><p></p><p>In prospective surveillance of 4005 infants born after the 1964 rubella epidemic in the United States, 68 percent of infected newborns had subclinical infection during the neonatal period [<a href="#rid54">54</a>]. However, 71 percent of those who were followed developed clinical manifestations in the first five years of life. The lack of clinical manifestations during the newborn period and the risk for progression highlight the importance of timely diagnosis and appropriate short- and long-term management [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Late manifestations</span><span class="headingEndMark"> — </span>Delayed manifestations occur in at least 20 percent of children with CRS [<a href="#rid61">61</a>]. Some of the late manifestations may relate to subtle damage that is present but not detected in early life. Late manifestations include [<a href="#rid61">61</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hearing loss</strong> – Permanent hearing loss is the most common late manifestation of CRI, ultimately occurring in up to 80 percent of patients [<a href="#rid31">31,58</a>]. SNHL is usually bilateral. It ranges in severity from mild to profound and may progress over time. Rarely, sudden onset of hearing loss may occur after years of normal hearing [<a href="#rid63">63,64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endocrine disorders</strong> – Late manifestations of intrauterine rubella infection may include diabetes, thyroid disease, and growth hormone deficiency [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1">In the available case series, approximately 1 percent of individuals with CRS developed diabetes in childhood and adolescence [<a href="#rid41">41,65-67</a>]. The risk increases in adulthood. In long-term follow-up of patients with CRS following the 1941 rubella epidemic in Australia, 22 percent developed diabetes by age 60 years (compared with a background prevalence of approximately 10 to 15 percent) [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus", section on 'Role of viruses'</a>.)</p><p></p><p class="bulletIndent1">Thyroid dysfunction affects approximately 5 percent of patients with CRS. It manifests as hyperthyroidism, hypothyroidism, and thyroiditis [<a href="#rid68">68-72</a>]. A high prevalence of thyroid microsomal or thyroglobulin antibodies has been observed in patients with CRS, suggesting that immune-mediated mechanisms may play a role, but there is no clear evidence that congenital rubella predisposes to autoimmunity. (See  <a class="medical medical_review" href="/d/html/5841.html" rel="external">"Clinical manifestations and diagnosis of Graves disease in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/5838.html" rel="external">"Acquired hypothyroidism in childhood and adolescence"</a> and <a class="local">'Immunologic response'</a> above.)</p><p></p><p class="bulletIndent1">CRS may occasionally be associated with growth hormone deficiency and short stature [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/d/html/5842.html" rel="external">"Diagnosis of growth hormone deficiency in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eye problems</strong> – Late-onset ophthalmologic manifestations of CRS may include pigmentary retinopathy (in approximately 40 to 60 percent of cases)  (<a class="graphic graphic_picture graphicRef70003" href="/d/graphic/70003.html" rel="external">picture 2</a>), cataracts, glaucoma (in 2 to 15 percent of cases), keratic precipitates, keratoconus, corneal hydrops, microphthalmos (estimated to occur in 10 to 20 percent of cases), strabismus, and absorption of the cataractous lens [<a href="#rid58">58,61,74,75</a>]. This damage can appear years or even decades after birth [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular disease</strong> – Vascular sequelae of CRS may include fibromuscular proliferation of the intima, sclerosis of arteries, systemic hypertension secondary to renal disease, and subretinal neovascularization [<a href="#rid61">61,62</a>]. These lesions are potential causes of coronary, cerebral, and peripheral vascular disease in adulthood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Panencephalitis</strong> – Progressive rubella panencephalitis most commonly occurs in the second decade of life [<a href="#rid76">76,77</a>]. It is slowly progressive and fatal. The initial findings are usually learning problems and ataxia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune defects</strong> – Defects in specific antibody production, repeated infections, and defective T cell response with associated autoimmune phenomena have been observed in patients with CRS [<a href="#rid78">78,79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prolonged viral shedding</strong> – After fetal infection, rubella virus persists throughout gestation and for months postnatally. It can be recovered from multiple sites.</p><p></p><p class="bulletIndent1">Pharyngeal shedding of rubella virus is common, prolonged, and intense during the months after delivery. At one year of age, as many as 20 percent of infants with CRS continue to shed rubella virus in the pharynx, but by two years of age, pharyngeal shedding is rare [<a href="#rid49">49,80-84</a>].</p><p></p><p class="bulletIndent1">In patients with ocular and CNS involvement (eg, cataracts, late subacute panencephalitis), rubella virus has been cultured from the crystalline lens and cerebrospinal fluid in children older than one year of age [<a href="#rid77">77,80,85,86</a>].</p><p></p><p class="headingAnchor" id="H2325618485"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H326182425"><span class="h2">Clinical suspicion</span><span class="headingEndMark"> — </span>The possibility of congenital rubella infection (CRI) should be considered in [<a href="#rid1">1,87</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Any infant born to a woman who had documented or suspected rubella infection at any time during pregnancy; treatment of maternal rubella infection with immunoglobulin does not guarantee protection from fetal infection (see  <a class="medical medical_review" href="/d/html/8312.html" rel="external">"Rubella in pregnancy", section on 'Treatment'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Any infant born in a region where rubella is endemic who has fetal growth restriction or other clinical manifestations suggestive of congenital rubella syndrome (CRS)  (<a class="graphic graphic_table graphicRef75721" href="/d/graphic/75721.html" rel="external">table 2</a>) </p><p></p><p class="headingAnchor" id="H2257471130"><span class="h2">Components of the evaluation</span><span class="headingEndMark"> — </span>The evaluation of a newborn with suspected CRI or CRS includes [<a href="#rid1">1,25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Review of maternal history to confirm documentation of rubella immunity</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete physical examination assessing for stigmata consistent with the syndrome  (<a class="graphic graphic_table graphicRef75721" href="/d/graphic/75721.html" rel="external">table 2</a>) (see <a class="local">'Clinical features'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver enzymes and bilirubin (total and direct)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lumbar puncture</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Echocardiography </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiographs of long bones</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ophthalmologic evaluation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Audiologic evaluation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neuroimaging (eg, ultrasonography, computed tomography) [<a href="#rid88">88</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rubella serology (see <a class="local">'Serology'</a> below)</p><p></p><p class="headingAnchor" id="H3236108182"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H2828934282"><span class="h2">Laboratory confirmation</span><span class="headingEndMark"> — </span>Laboratory confirmation of congenital rubella infection (CRI) can be established with <strong>any</strong> of the following  (<a class="graphic graphic_table graphicRef55913" href="/d/graphic/55913.html" rel="external">table 1</a>) [<a href="#rid89">89</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Demonstration of rubella-specific IgM antibodies (see <a class="local">'Serology'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Demonstration of rubella-specific IgG antibodies that persist at a higher concentration or longer duration than expected from transfer of maternal antibody (ie, titer does not drop at the expected rate of a twofold dilution per month) (see <a class="local">'Serology'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Isolation of rubella in viral culture from a nasopharyngeal swab, blood sample (including cord blood), urine, or cerebrospinal fluid (see <a class="local">'Viral culture'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Detection of rubella virus RNA by polymerase chain reaction (PCR) (see <a class="local">'Polymerase chain reaction'</a> below)</p><p></p><p>Laboratory evaluation should be performed before the child reaches one year of age, after which it is difficult to establish a diagnosis of CRI [<a href="#rid90">90</a>]. This is because the patient will have received rubella vaccine by this age and would be expected to have detectable IgG. Other viral detection tests generally have very low yield after 12 months. (See <a class="local">'Retrospective diagnosis'</a> below.)</p><p>The cost, length of time required for definitive results, and expertise required for performance of these tests vary. Demonstration of rubella-specific IgM antibodies with commercially available enzyme immunoassay kits is the preferred initial test, particularly for infants in the first two months after birth [<a href="#rid1">1,91</a>]. Infants with clinical findings of CRS who test negative soon after birth should be retested later in infancy. Approximately 20 percent of infected infants tested for rubella IgM may not have detectable titers before age one month.</p><p>Measurement of rubella-specific IgG is most helpful in infants between 6 and 12 months of age [<a href="#rid1">1,49</a>]. </p><p>Consultation with an expert in pediatric infectious diseases is suggested if there are questions regarding the appropriate diagnostic strategy.</p><p class="headingAnchor" id="H2029748797"><span class="h2">Case definition</span><span class="headingEndMark"> — </span>The case definition for congenital rubella syndrome (CRS)/CRI used by the Centers for Disease Control and Prevention (CDC) is based upon both clinical and laboratory criteria. Depending on the findings, cases are classified as "suspected," "probable," "confirmed," or "infection only," as outlined in the table  (<a class="graphic graphic_table graphicRef55913" href="/d/graphic/55913.html" rel="external">table 1</a>) [<a href="#rid89">89,92</a>].</p><p class="headingAnchor" id="H896398630"><span class="h2">Retrospective diagnosis</span><span class="headingEndMark"> — </span>It is difficult to establish a diagnosis of CRI in children older than one year of age [<a href="#rid25">25,90</a>]. At this age, serologic testing is not diagnostic after rubella immunization and isolation of virus in culture is unlikely because viral shedding has typically waned by this age.</p><p>Retrospective diagnosis of CRI in children &gt;1 year old can be established with PCR, which is highly sensitive (see <a class="local">'Polymerase chain reaction'</a> below); however, PCR may not be available in all settings and it can be negative when performed in older children with CRI. In such cases, the following tests support the diagnosis of CRI:</p><p class="bulletIndent1"><span class="glyph">●</span>Measuring lymphocyte response to rubella in vitro [<a href="#rid33">33,93,94</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measuring rubella IgG avidity (strength of antigen-antibody binding); children with intrauterine rubella infection have low rubella-specific IgG avidity [<a href="#rid22">22,25,95-98</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measuring antibody response to rubella vaccination (in children with compatible manifestations but nondetectable antibody); children with CRS generally do not respond to rubella vaccination [<a href="#rid22">22,24,28,33,34</a>] (see <a class="local">'Immunologic response'</a> above)</p><p></p><p class="headingAnchor" id="H2782975547"><span class="h2">Laboratory tests for diagnosis</span></p><p class="headingAnchor" id="H3562429632"><span class="h3">Serology</span><span class="headingEndMark"> — </span>Serologic confirmation of CRI consists of demonstration of rubella-specific IgM antibody or infant IgG rubella antibody level that persists at a higher level and for a longer time than expected from intrauterine transfer of maternal antibody [<a href="#rid87">87,89</a>]. Serologic testing is more likely to be available in developing countries [<a href="#rid1">1</a>]. (See <a class="local">'Immunologic response'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Rubella-specific IgM antibody – Detection of rubella-specific IgM antibody in the neonatal serum or cord blood provides laboratory evidence of recent postnatal or CRI in the newborn [<a href="#rid22">22,31,87</a>]. IgM testing is most helpful in infants younger than two months, although IgM may be detectable for as long as 12 months in some infants [<a href="#rid1">1</a>]. Infants with symptoms consistent with CRS who test negative soon after birth should be retested at age one month because approximately 20 percent of infected infants tested for rubella IgM may not have detectable titers before age one month [<a href="#rid87">87</a>]. In infants older than two months, positive IgM is helpful, but negative IgM does not exclude infection. False-positive IgM results may be caused by rheumatoid factor, parvovirus, and heterophile antibodies [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rubella-specific IgG antibody – Monitoring rubella-specific IgG over time (eg, at 3, 6, and, if necessary, 12 months of age) also may confirm congenital or recent postnatal rubella infection if rubella-specific IgG persists at a higher level and for a longer time than would be expected for maternal IgG [<a href="#rid87">87,89</a>]. Maternal rubella antibody has a half-life of approximately 30 days; it should decrease by four- to eightfold by three months of age and should disappear by 6 to 12 months of age [<a href="#rid25">25,31,87</a>]. (See <a class="local">'Immunologic response'</a> above.)</p><p></p><p class="bulletIndent1">Monitoring rubella-specific IgG is less desirable than the other methods of laboratory diagnosis because it may delay diagnosis, does not necessarily distinguish congenital from postnatal infection, and does not absolutely exclude intrauterine infection (if the infant has low antibody levels because of agammaglobulinemia or dysgammaglobulinemia) [<a href="#rid25">25,87</a>]. In questionable cases, assessment of IgG rubella antibody avidity (available at specialized laboratories or at the CDC) may be helpful [<a href="#rid95">95,96</a>]. (See <a class="local">'Retrospective diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H395716149"><span class="h3">Viral culture</span><span class="headingEndMark"> — </span>The diagnosis of CRI can be confirmed by the isolation of the rubella virus in culture [<a href="#rid1">1</a>]. Rubella virus is most frequently isolated from nasopharyngeal secretions, although it can also be cultured from blood (including cord blood), placenta, urine, and cerebrospinal fluid [<a href="#rid31">31,87</a>]. Specialized testing is necessary for rubella virus, so laboratory personnel should be notified that rubella virus is suspected [<a href="#rid90">90</a>].</p><p>Virus isolation should be attempted as soon as congenital rubella is suspected because viral excretion wanes during infancy [<a href="#rid31">31</a>]. Isolation of rubella virus may be possible for several years from lens tissue in children with cataracts or cerebrospinal fluid in children with encephalitis [<a href="#rid77">77,85</a>].</p><p class="headingAnchor" id="H1057279320"><span class="h3">Polymerase chain reaction</span><span class="headingEndMark"> — </span>Detection of rubella virus RNA by PCR also confirms CRI [<a href="#rid87">87,89,90</a>] but may not be available in all settings [<a href="#rid1">1</a>]. PCR may be performed on pharyngeal swabs, respiratory secretions, cerebrospinal fluid, amniotic fluid, products of conception, urine, and lens tissue (in children with ocular anomalies), and other tissue specimens [<a href="#rid22">22,90,99-101</a>].</p><p class="headingAnchor" id="H263857150"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Congenital rubella syndrome (CRS) must be differentiated from other congenital infections  (<a class="graphic graphic_table graphicRef76743" href="/d/graphic/76743.html" rel="external">table 3</a>) and other conditions that have similar manifestations in the newborn. Appropriate viral testing and serologies will distinguish congenital rubella infection (CRI) from these other causes:</p><p class="bulletIndent1"><span class="glyph">●</span>Congenital toxoplasmosis (see  <a class="medical medical_review" href="/d/html/14426.html" rel="external">"Congenital toxoplasmosis: Clinical features and diagnosis", section on 'Evaluation'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital cytomegalovirus (see  <a class="medical medical_review" href="/d/html/14430.html" rel="external">"Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Clinical manifestations'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital syphilis (see  <a class="medical medical_review" href="/d/html/14428.html" rel="external">"Congenital syphilis: Clinical manifestations, evaluation, and diagnosis", section on 'Evaluation and diagnosis'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital Zika virus infection (see  <a class="medical medical_review" href="/d/html/107211.html" rel="external">"Zika virus infection: Evaluation and management of pregnant patients", section on 'Congenital infection'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital lymphocytic choriomeningitis virus (see  <a class="medical medical_review" href="/d/html/5980.html" rel="external">"Viral meningitis in children: Epidemiology, pathogenesis, and etiology", section on 'Lymphocytic choriomeningitis virus'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other conditions that cause sensorineural hearing loss (SNHL)  (<a class="graphic graphic_table graphicRef119919" href="/d/graphic/119919.html" rel="external">table 4</a>) (see  <a class="medical medical_review" href="/d/html/6308.html" rel="external">"Hearing loss in children: Etiology", section on 'Congenital'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other conditions that cause cataracts  (<a class="graphic graphic_table graphicRef78696" href="/d/graphic/78696.html" rel="external">table 5</a>) (see  <a class="medical medical_review" href="/d/html/6270.html" rel="external">"Cataract in children", section on 'Etiology'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other conditions that are associated with congenital heart disease (eg, genetic syndromes, gestational diabetes) (see  <a class="medical medical_review" href="/d/html/5774.html" rel="external">"Identifying newborns with critical congenital heart disease", section on 'Risk factors'</a>)</p><p></p><p class="headingAnchor" id="H1358540072"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Supportive care and surveillance are the cornerstones of management for congenital rubella infection (CRI).</p><p class="headingAnchor" id="H34009289"><span class="h2">No role for antiviral therapy</span><span class="headingEndMark"> — </span>The clinical course of intrauterine CRI or subsequent congenital rubella syndrome (CRS) is not altered by treatment with antiviral or biologic agents [<a href="#rid31">31,32,102,103</a>], nor are there any agents that have any long-term effect on the duration of viral shedding.</p><p class="headingAnchor" id="H2694944930"><span class="h2">Management of complications</span><span class="headingEndMark"> — </span>Most infants with CRS have multiple medical problems and require multidisciplinary management [<a href="#rid31">31</a>]. At the time of diagnosis, a comprehensive evaluation should be performed to determine the extent of disease severity. (See <a class="local">'Evaluation'</a> above.)</p><p>The medical problems that may occur in CRS are generally managed in the same manner as in patients without CRI [<a href="#rid104">104</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hearing loss – Hearing loss may require hearing aids and referral to an early intervention program. (See  <a class="medical medical_review" href="/d/html/6298.html" rel="external">"Hearing loss in children: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eye disease – Cataracts, retinopathy, infantile glaucoma, and other eye complications require specialized management by a pediatric eye care specialist. (See  <a class="medical medical_review" href="/d/html/6272.html" rel="external">"Overview of glaucoma in infants and children"</a> and  <a class="medical medical_review" href="/d/html/6270.html" rel="external">"Cataract in children", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system (CNS) manifestations – In the early postnatal period, CNS disease may manifest as meningoencephalitis (eg, abnormal neurologic findings, seizures). Provision of empiric antimicrobial therapy until culture or polymerase chain reaction (PCR) results for bacterial and viral pathogens of cerebrospinal fluid results are available and supportive care are the cornerstones of therapy for meningoencephalitis in neonates. Initial supportive care measures may include stabilization of cardiorespiratory status and treatment of seizures. (See  <a class="medical medical_review" href="/d/html/6016.html" rel="external">"Bacterial meningitis in the neonate: Treatment and outcome"</a> and  <a class="medical medical_review" href="/d/html/6201.html" rel="external">"Treatment of neonatal seizures"</a>.)</p><p></p><p class="bulletIndent1">After infancy, CNS manifestations may include intellectual disability, autism, and cerebral palsy, which may require special education services and speech, language, occupational, and/or physical therapy. (See  <a class="medical medical_review" href="/d/html/6191.html" rel="external">"Intellectual disability (ID) in children: Management, outcomes, and prevention"</a> and  <a class="medical medical_review" href="/d/html/6176.html" rel="external">"Cerebral palsy: Overview of management and prognosis"</a> and  <a class="medical medical_review" href="/d/html/607.html" rel="external">"Autism spectrum disorder in children and adolescents: Behavioral and educational interventions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital heart disease – Cardiac evaluation and management is the same as for infants without CRS. Patent ductus arteriosus and pulmonary stenosis are the most common lesions [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/d/html/5774.html" rel="external">"Identifying newborns with critical congenital heart disease"</a> and  <a class="medical medical_review" href="/d/html/5771.html" rel="external">"Management of patent ductus arteriosus (PDA) in term infants, children, and adults"</a> and  <a class="medical medical_review" href="/d/html/114558.html" rel="external">"Pulmonic stenosis in infants and children: Management and outcome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endocrine abnormalities – The late-onset endocrine abnormalities (eg, diabetes mellitus [DM], thyroid dysfunction) should be managed by an endocrinologist. Parents/caregivers should be counselled about the risk of type 1 DM, including signs to watch for (eg, polyuria, polydipsia, weight loss) to promote early detection of this complication and avoid development of diabetic ketoacidosis. (See  <a class="medical medical_review" href="/d/html/5817.html" rel="external">"Overview of the management of type 1 diabetes mellitus in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/5854.html" rel="external">"Treatment and prognosis of Graves disease in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/5838.html" rel="external">"Acquired hypothyroidism in childhood and adolescence"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal thrombocytopenia – Thrombocytopenia is generally mild to moderate and transient. Although purpura and petechiae may be severe, clinically significant bleeding is uncommon. (See  <a class="medical medical_review" href="/d/html/97752.html" rel="external">"Neonatal thrombocytopenia: Clinical manifestations, evaluation, and management", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal respiratory distress – Neonates with respiratory distress should be managed with oxygen or ventilatory (invasive or noninvasive) support as necessary. (See  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Clinical approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal hyperbilirubinemia – CRS is associated with direct (conjugated) hyperbilirubinemia that is rarely severe and generally does not require any specific therapy [<a href="#rid104">104</a>]. If the infant has concomitant unconjugated hyperbilirubinemia that requires treatment with phototherapy, there is a risk of developing bronze baby syndrome from the conjugated component. Phototherapy should generally be avoided if the infant has predominantly conjugated bilirubin (ie, if the direct [conjugated] component makes up &gt;50 percent of the total bilirubin level). This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5063.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management", section on 'Adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H1117723864"><span class="h2">Surveillance and long-term follow-up</span><span class="headingEndMark"> — </span>Patients with CRI require lifelong follow-up care and surveillance. Clinical manifestations of CRS typically develop or worsen over time  (<a class="graphic graphic_table graphicRef75721" href="/d/graphic/75721.html" rel="external">table 2</a>). Hearing loss usually has onset during the first several years of life, but other manifestations may manifest later in childhood, adolescence, or adulthood [<a href="#rid27">27,50,55-57,105</a>].</p><p>Infants with CRI require close monitoring during the first 6 to 12 months of life, particularly for hearing impairment and developmental abnormalities [<a href="#rid31">31,104</a>]. These are among the most frequent late CRS manifestations and often occur in infants who were asymptomatic at birth. Repeat assessment over time is necessary to detect new or progressive manifestations.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hearing assessments</strong> – Hearing loss is the most common manifestation of CRS, and prompt diagnosis and institution of early intervention and educational programs are among the most important aspects of management [<a href="#rid1">1,104</a>].</p><p></p><p class="bulletIndent1">Infants exposed to rubella virus in utero should undergo objective hearing assessment during the neonatal period, at least once between 24 and 30 months of age (preferably more frequently) and then according to the American Academy of Pediatrics periodicity schedule (whether or not the infant has other manifestations of congenital rubella syndrome [CRS]) [<a href="#rid104">104,106,107</a>]. (See  <a class="medical medical_review" href="/d/html/6297.html" rel="external">"Hearing loss in children: Screening and evaluation", section on 'Screening for hearing loss in children'</a>.)</p><p></p><p class="bulletIndent1">If hearing loss is detected, the child should be referred for early intervention services and fitted with an appropriate amplification device [<a href="#rid104">104</a>]. (See  <a class="medical medical_review" href="/d/html/6298.html" rel="external">"Hearing loss in children: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vision assessment and follow-up eye examination</strong> – All children with CRS should have routine vision screening performed at each primary care visit and should have regular follow-up with a pediatric eye care specialist. The frequency of follow-up will depend on whether an eye problem is identified and, if so, what type and how severe it is. Patients who develop new concerning findings (vision changes, leukocoria, excessive tearing) should be referred for more urgent ophthalmologic evaluation. (See  <a class="medical medical_review" href="/d/html/6261.html" rel="external">"Vision screening and assessment in infants and children"</a> and  <a class="medical medical_review" href="/d/html/6270.html" rel="external">"Cataract in children", section on 'Follow-up'</a> and  <a class="medical medical_review" href="/d/html/6272.html" rel="external">"Overview of glaucoma in infants and children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Developmental-behavioral screening</strong> – Children with CRS are at increased risk for developmental problems. Developmental surveillance and screening are essential components of long-term care. (See  <a class="medical medical_review" href="/d/html/615.html" rel="external">"Developmental-behavioral surveillance and screening in primary care"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac follow-up</strong> – Patients with CRS-related congenital heart disease require regular follow-up with a pediatric cardiologist. The frequency of follow-up depends upon the specific defect and whether any intervention has been performed. Clinicians should ask about any new or worsening cardiac symptoms at all routine visits. In infants, this includes lethargy and tiring feeds, trouble coordinating feeding and breathing, respiratory distress, and excessive sweating. Concerning symptoms in older children include exercise intolerance, chest pain, and syncope. If these are present, the patient should follow up with their cardiologist more urgently. (See  <a class="medical medical_review" href="/d/html/5765.html" rel="external">"Suspected heart disease in infants and children: Criteria for referral", section on 'Symptoms'</a>.)</p><p></p><p class="bulletIndent1">It is important to screen for cardiac symptoms even in patients whose initial evaluation was negative for congenital heart disease since some lesions may be mild initially and then progress over time (eg, pulmonic or aortic valve stenosis). (See  <a class="medical medical_review" href="/d/html/14578.html" rel="external">"Pulmonic stenosis in infants and children: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5775.html" rel="external">"Valvar aortic stenosis in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening for diabetes and thyroid disease</strong> – It is important to monitor children with CRS for the development of diabetes and thyroid disease. Patients and parents/caregivers should be educated about the signs and symptoms of these conditions. Health care providers should ask about symptoms and signs at health maintenance visits. Patients with clinical manifestations should undergo appropriate testing. Antithyroid antibodies may be measured as surrogate markers of disease. (See  <a class="medical medical_review" href="/d/html/5816.html" rel="external">"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/5841.html" rel="external">"Clinical manifestations and diagnosis of Graves disease in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/5838.html" rel="external">"Acquired hypothyroidism in childhood and adolescence"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune deficiency</strong> – A small number of patients with CRS have low levels of serum IgG [<a href="#rid104">104</a>]. Serum immunoglobulins should be measured when clinically indicated (eg, in children with recurrent infections). (See  <a class="medical medical_review" href="/d/html/5949.html" rel="external">"Approach to the child with recurrent infections"</a>.)</p><p></p><p class="headingAnchor" id="H1416370902"><span class="h1">OUTCOME</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perinatal mortality</strong> – Most newborns with congenital rubella infection (CRI) survive. However, perinatal and early postnatal death can occur in extremely preterm neonates and those with severe disease. Severe manifestations in these fatal cases can include extensive meningoencephalitis, severe cardiac lesions or myocarditis with early heart failure, fulminant interstitial pneumonitis, and rapidly progressive hepatitis [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term outcome</strong> – Information on the long-term outcome of congenital rubella syndrome (CRS) is provided in a series of follow-up studies of a cohort of 50 patients born during the 1939 to 1943 rubella epidemic in Australia [<a href="#rid55">55-57</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At 25 years, 48 of 50 patients were deaf; 43 of the 48 had severe bilateral deafness; and hearing impairment was detected in all patients by seven years of age, in most patients by three years of age, but in only five patients by one year of age.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At 25 years, 11 patients had congenital cardiovascular defects (patent ductus arteriosus, pulmonary stenosis, elevated systemic blood pressure); only two of these were detected in the first year of life. At 60 years, 21 of 32 patients had mild aortic valve sclerosis on echocardiography and 12 were being treated for hypertension.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At 25 years, 26 of 50 patients had typical rubella cataracts or chorioretinopathy; at 60 years, virtually all 32 patients had ocular conditions: rubella retinopathy (12), glaucoma (8), cataracts with onset between the 50- and 60-year follow-up (3), blindness (1), and other ocular conditions (8).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At 25 years, 50 percent of patients were below the 10<sup>th</sup> percentile for weight and/or height; at 50 years, 6 of 40 patients (15 percent) were below the 3<sup>rd</sup> percentile for height.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At 50 years, 5 of 40 patients (12.5 percent) were diabetic; at 60 years, the prevalence of type 2 diabetes (22 percent), thyroid disorders (19 percent), early menopause (73 percent), and osteoporosis (12.5 percent) was increased compared with the Australian population.</p><p></p><p class="headingAnchor" id="H1074548775"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Prevention is the most important aspect of management of congenital rubella infection (CRI).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccine</strong> – All children should be vaccinated against rubella in early childhood. Measles, mumps, and rubella immunization are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents", section on 'Measles, mumps, and rubella disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testing in pregnancy</strong> – In pregnant individuals, immunity to rubella should be documented as part of initial prenatal care. Rubella in pregnancy is discussed in detail in a separate topic review. (See  <a class="medical medical_review" href="/d/html/8312.html" rel="external">"Rubella in pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of transmission</strong> – Rubella virus is spread from person to person via airborne transmission or droplets shed from respiratory secretions [<a href="#rid108">108</a>]. It may be transmitted by persons with subclinical or asymptomatic infection.</p><p></p><p class="bulletIndent1">Newborns with congenital rubella syndrome (CRS)/CRI remain actively infected and contagious at the time of birth [<a href="#rid104">104</a>]. Droplet precautions should be instituted for hospitalized patients as soon as CRS/CRI is suspected [<a href="#rid31">31</a>]. Only individuals known to be rubella immune should care for contagious or potentially contagious patients [<a href="#rid109">109</a>].</p><p></p><p class="bulletIndent1">No special precautions are necessary for vaccinated household contacts of infants with congenital rubella syndrome (CRS/CRI) [<a href="#rid104">104</a>]. However, the family should be advised about the potential risks to pregnant visitors.</p><p></p><p class="bulletIndent1">Children with CRS/CRI are considered to be contagious until at least one year of age unless two clinical specimens obtained one month apart are negative for rubella virus by culture or by polymerase chain reaction (PCR) after three months of age [<a href="#rid87">87,110</a>]. In childcare settings, children with CRS/CRI who remain contagious should be cared for only by individuals who are immune to rubella (ie, have received at least one dose of rubella-containing vaccine on or after the first birthday or have a positive serologic test for rubella-specific IgG antibody) [<a href="#rid87">87</a>].</p><p></p><p class="headingAnchor" id="H22"><span class="h1">CASE REPORTING</span><span class="headingEndMark"> — </span>Cases of congenital rubella infection (CRI) and congenital rubella syndrome (CRS), whether suspected or confirmed, in the United States should be reported to the Centers for Disease Control and Prevention (CDC) through local and state health departments [<a href="#rid87">87,89</a>]. These cases should be reported as soon as they are suspected, even if laboratory confirmation is pending. Cases of CRI/CRS may indicate the presence of rubella infections in the community that may previously have been unrecognized and should trigger intensified surveillance for rubella and CRS [<a href="#rid87">87</a>]. In the United States, CRS is exceedingly rare and typically presents in newborns or infants born to immigrant mothers or susceptible women who travelled to areas of the world where rubella is still endemic [<a href="#rid111">111,112</a>].</p><p class="headingAnchor" id="H3531364502"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111578.html" rel="external">"Society guideline links: TORCH infections"</a>.)</p><p class="headingAnchor" id="H182187777"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83164.html" rel="external">"Patient education: Rubella (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectrum of congenital rubella infection</strong> – The clinical spectrum of congenital rubella infection (CRI) is broad, ranging from miscarriage or stillbirth, to congenital rubella syndrome (CRS; which can include various birth defects), to asymptomatic infection. (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – CRI is rare in countries with established rubella immunization programs. The risk of maternal-fetal transmission and clinical manifestations of CRI vary with the timing of maternal infection. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Pathogenesis'</a> above and  <a class="medical medical_review" href="/d/html/8312.html" rel="external">"Rubella in pregnancy", section on 'Congenital rubella syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features of CRS</strong> – Sensorineural hearing loss (SNHL), cataracts  (<a class="graphic graphic_picture graphicRef64979" href="/d/graphic/64979.html" rel="external">picture 1</a>), and congenital heart disease are the classic manifestations of CRS  (<a class="graphic graphic_table graphicRef55913" href="/d/graphic/55913.html" rel="external">table 1</a>). However, rubella virus may affect virtually every organ in the developing fetus  (<a class="graphic graphic_table graphicRef75721" href="/d/graphic/75721.html" rel="external">table 2</a>). (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – The evaluation of an infant with suspected CRI or CRS includes (see <a class="local">'Components of the evaluation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Review of maternal history for documentation of rubella immunity</p><p class="bulletIndent2"><span class="glyph">•</span>Complete physical examination</p><p class="bulletIndent2"><span class="glyph">•</span>Blood tests, including complete blood count, liver enzymes and bilirubin, and rubella serologies</p><p class="bulletIndent2"><span class="glyph">•</span>Lumbar puncture</p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac evaluation</p><p class="bulletIndent2"><span class="glyph">•</span>Radiographs of long bones</p><p class="bulletIndent2"><span class="glyph">•</span>Ophthalmologic evaluation</p><p class="bulletIndent2"><span class="glyph">•</span>Audiologic evaluation</p><p class="bulletIndent2"><span class="glyph">•</span>Neuroimaging (eg, ultrasonography, computed tomography)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory confirmation</strong> – Laboratory confirmation of CRI can be established with <strong>any</strong> of the following  (<a class="graphic graphic_table graphicRef55913" href="/d/graphic/55913.html" rel="external">table 1</a>) (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Demonstration of rubella-specific immunoglobulin M (IgM) antibody (see <a class="local">'Serology'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Demonstration of rubella-specific immunoglobulin G (IgG) antibody that persist at a higher concentration or longer duration than expected from passive transfer of maternal antibody (see <a class="local">'Serology'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Isolation of rubella virus in viral culture from a nasopharyngeal swab, blood sample (including cord blood), urine, or cerebrospinal fluid (see <a class="local">'Viral culture'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Detection of rubella virus RNA by polymerase chain reaction (PCR) (see <a class="local">'Polymerase chain reaction'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Case definition</strong> – The case definitions for CRI and CRS used by the Centers for Disease Control and Prevention are based upon both clinical and laboratory criteria. Depending on the findings, cases are classified as "suspected," "probable," "confirmed," or "infection only," as outlined in the table  (<a class="graphic graphic_table graphicRef55913" href="/d/graphic/55913.html" rel="external">table 1</a>). (See <a class="local">'Case definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis for CRS includes other intrauterine infections  (<a class="graphic graphic_table graphicRef76743" href="/d/graphic/76743.html" rel="external">table 3</a>) and other conditions that can cause SNHL  (<a class="graphic graphic_table graphicRef119919" href="/d/graphic/119919.html" rel="external">table 4</a>), cataracts  (<a class="graphic graphic_table graphicRef78696" href="/d/graphic/78696.html" rel="external">table 5</a>), and congenital heart disease. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– Supportive care and surveillance are the cornerstones of management for CRI. Antiviral therapy is <strong>not</strong> used, because it does not alter the course. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1">Most infants with CRS have multiple medical problems  (<a class="graphic graphic_table graphicRef75721" href="/d/graphic/75721.html" rel="external">table 2</a>) and require multidisciplinary management. The medical problems that occur in CRS are generally managed in the same manner as in patients without CRI. (See <a class="local">'Management of complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term follow-up</strong> – Patients with CRI require lifelong follow-up care and surveillance. Clinical manifestations of CRS may develop over time  (<a class="graphic graphic_table graphicRef75721" href="/d/graphic/75721.html" rel="external">table 2</a>). Hearing loss usually has onset early in infancy but may worsen during the first several years of life. Other manifestations may present later in childhood, adolescence, or adulthood. (See <a class="local">'Surveillance and long-term follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Prevention is the most important aspect of management of CRI. Preventive measures include immunization in early childhood and documenting rubella immunity early in pregnancy. (See  <a class="medical medical_review" href="/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents"</a> and  <a class="medical medical_review" href="/d/html/8312.html" rel="external">"Rubella in pregnancy"</a>.)</p><p></p><p class="headingAnchor" id="H1263260994"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Simon R Dobson, MD, FRCP(C), who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Reef SE, Plotkin S, Cordero JF, et al. Preparing for elimination of congenital Rubella syndrome (CRS): summary of a workshop on CRS elimination in the United States. Clin Infect Dis 2000; 31:85.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Elimination of rubella and congenital rubella syndrome--United States, 1969-2004. MMWR Morb Mortal Wkly Rep 2005; 54:279.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Progress toward elimination of rubella and congenital rubella syndrome--the Americas, 2003-2008. MMWR Morb Mortal Wkly Rep 2008; 57:1176.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Progress toward elimination of measles and prevention of congenital rubella infection--European region, 1990-2004. MMWR Morb Mortal Wkly Rep 2005; 54:175.</a></li><li><a class="nounderline abstract_t">Zimmerman LA, Knapp JK, Antoni S, et al. Progress Toward Rubella and Congenital Rubella Syndrome Control and Elimination - Worldwide, 2012-2020. MMWR Morb Mortal Wkly Rep 2022; 71:196.</a></li><li><a class="nounderline abstract_t">Eurosurveillance editorial team. The Americas region declares that rubella has been eliminated. Euro Surveill 2015; 20.</a></li><li class="breakAll">US Center for Disease Control and Prevention. Rubella in the US. Available at: https://www.cdc.gov/rubella/about/in-the-us.html.</li><li><a class="nounderline abstract_t">Webster WS. Teratogen update: congenital rubella. Teratology 1998; 58:13.</a></li><li><a class="nounderline abstract_t">Woods WA, Johnson RT, Hostetler DD, et al. Immunofluorescent studies on rubella-infected tissue cultures and human tissues. J Immunol 1966; 96:253.</a></li><li><a class="nounderline abstract_t">Rawls WE. Congenital rubella: the significance of virus persistence. Prog Med Virol 1968; 10:238.</a></li><li><a class="nounderline abstract_t">Rorke LB, Spiro AJ. Cerebral lesions in congenital rubella syndrome. J Pediatr 1967; 70:243.</a></li><li><a class="nounderline abstract_t">Miller E, Cradock-Watson JE, Pollock TM. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet 1982; 2:781.</a></li><li><a class="nounderline abstract_t">Cooper LZ. The history and medical consequences of rubella. Rev Infect Dis 1985; 7 Suppl 1:S2.</a></li><li><a class="nounderline abstract_t">Naeye RL, Blanc W. Pathogenesis of congenital rubella. JAMA 1965; 194:1277.</a></li><li><a class="nounderline abstract_t">Lee JY, Bowden DS. Rubella virus replication and links to teratogenicity. Clin Microbiol Rev 2000; 13:571.</a></li><li><a class="nounderline abstract_t">PLOTKIN SA, BOUE A, BOUE JG. THE IN VITRO GROWTH OF RUBELLA VIRUS IN HUMAN EMBRYO CELLS. Am J Epidemiol 1965; 81:71.</a></li><li><a class="nounderline abstract_t">Vaheri A, Cristofalo VJ. Metabolism of rubella virus-infected BHK 21 cells. Enhanced glycolysis and late cellular inhibition. Arch Gesamte Virusforsch 1967; 21:425.</a></li><li><a class="nounderline abstract_t">Plotkin SA, Vaheri A. Human fibroblasts infected with rubella virus produce a growth inhibitor. Science 1967; 156:659.</a></li><li><a class="nounderline abstract_t">Duncan R, Muller J, Lee N, et al. Rubella virus-induced apoptosis varies among cell lines and is modulated by Bcl-XL and caspase inhibitors. Virology 1999; 255:117.</a></li><li><a class="nounderline abstract_t">Adamo P, Asís L, Silveyra P, et al. Rubella virus does not induce apoptosis in primary human embryo fibroblast cultures: a possible way of viral persistence in congenital infection. Viral Immunol 2004; 17:87.</a></li><li><a class="nounderline abstract_t">Adamo MP, Zapata M, Frey TK. Analysis of gene expression in fetal and adult cells infected with rubella virus. Virology 2008; 370:1.</a></li><li><a class="nounderline abstract_t">Banatvala JE, Brown DW. Rubella. Lancet 2004; 363:1127.</a></li><li><a class="nounderline abstract_t">Buimovici-Klein E, Lang PB, Ziring PR, Cooper LZ. Impaired cell-mediated immune response in patients with congenital rubella: correlation with gestational age at time of infection. Pediatrics 1979; 64:620.</a></li><li><a class="nounderline abstract_t">Mauracher CA, Mitchell LA, Tingle AJ. Selective tolerance to the E1 protein of rubella virus in congenital rubella syndrome. J Immunol 1993; 151:2041.</a></li><li class="breakAll">Cherry J, Baker A.. Rubella virus.. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 8th ed., Cherry JD, Harrison GJ, Kaplan SL (Eds), Elsevier, Philadelphia 2019. p.1601.</li><li><a class="nounderline abstract_t">Cradock-Watson JE, Ridehalgh MK. Specific immunoglobulins in infants with the congenital rubella syndrome. J Hyg (Lond) 1976; 76:109.</a></li><li><a class="nounderline abstract_t">Peckham CS. Clinical and laboratory study of children exposed in utero to maternal rubella. Arch Dis Child 1972; 47:571.</a></li><li><a class="nounderline abstract_t">Cooper LZ, Florman AL, Ziring PR, Krugman S. Loss of rubella hemagglutination inhibition antibody in congenital rubella. Failure of seronegative children with congenital rubella to respond to HPV-77 rubella vaccine. Am J Dis Child 1971; 122:397.</a></li><li><a class="nounderline abstract_t">Kenrick KG, Slinn RF, Dorman DC, Menser MA. Immunoglobulins and rubella-virus antibodies in adults with congenital rubella. Lancet 1968; 1:548.</a></li><li><a class="nounderline abstract_t">Hardy JB, Sever JL, Gilkeson MR. Declining antibody titers in children with congenital rubella. J Pediatr 1969; 75:213.</a></li><li class="breakAll">Plotkin, SA, Reef, et al. Rubella. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington, JS, Klein, JO, Wilson, CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.861.</li><li><a class="nounderline abstract_t">Plotkin SA, Klaus RM, Whitely JP. Hypogammaglobulinemia in an infant with congenital rubella syndrome; failure of 1-adamantanamine to stop irus excretion. J Pediatr 1966; 69:1085.</a></li><li><a class="nounderline abstract_t">Hosking CS, Pyman C, Wilkins B. The nerve deaf child--intrauterine rubella or not? Arch Dis Child 1983; 58:327.</a></li><li><a class="nounderline abstract_t">Meitsch K, Enders G, Wolinsky JS, et al. The role of rubella-immunoblot and rubella-peptide-EIA for the diagnosis of the congenital rubella syndrome during the prenatal and newborn periods. J Med Virol 1997; 51:280.</a></li><li><a class="nounderline abstract_t">Verder H, Dickmeiss E, Haahr S, et al. Late-onset rubella syndrome: coexistence of immune complex disease and defective cytotoxic effector cell function. Clin Exp Immunol 1986; 63:367.</a></li><li><a class="nounderline abstract_t">Rabinowe SL, George KL, Loughlin R, et al. Congenital rubella. Monoclonal antibody-defined T cell abnormalities in young adults. Am J Med 1986; 81:779.</a></li><li><a class="nounderline abstract_t">Olson GB, South MA, Good RA. Phytohaemagglutinin unresponsiveness of lymphocytes from babies with congenital rubella. Nature 1967; 214:695.</a></li><li class="breakAll">Maldonado YA. Rubella virus. In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG (Eds), Elsevier Saunders, Edinburgh 2012. p.1112.</li><li><a class="nounderline abstract_t">Ginsberg-Fellner F, Witt ME, Fedun B, et al. Diabetes mellitus and autoimmunity in patients with the congenital rubella syndrome. Rev Infect Dis 1985; 7 Suppl 1:S170.</a></li><li><a class="nounderline abstract_t">Viskari H, Paronen J, Keskinen P, et al. Humoral beta-cell autoimmunity is rare in patients with the congenital rubella syndrome. Clin Exp Immunol 2003; 133:378.</a></li><li><a class="nounderline abstract_t">Gale EA. Congenital rubella: citation virus or viral cause of type 1 diabetes? Diabetologia 2008; 51:1559.</a></li><li><a class="nounderline abstract_t">Rubinstein P, Walker ME, Fedun B, et al. The HLA system in congenital rubella patients with and without diabetes. Diabetes 1982; 31:1088.</a></li><li><a class="nounderline abstract_t">Menser MA, Forrest JM, Bransby RD. Rubella infection and diabetes mellitus. Lancet 1978; 1:57.</a></li><li><a class="nounderline abstract_t">Hyöty H, Taylor KW. The role of viruses in human diabetes. Diabetologia 2002; 45:1353.</a></li><li><a class="nounderline abstract_t">Ou D, Jonsen LA, Metzger DL, Tingle AJ. CD4+ and CD8+ T-cell clones from congenital rubella syndrome patients with IDDM recognize overlapping GAD65 protein epitopes. Implications for HLA class I and II allelic linkage to disease susceptibility. Hum Immunol 1999; 60:652.</a></li><li><a class="nounderline abstract_t">Givens KT, Lee DA, Jones T, Ilstrup DM. Congenital rubella syndrome: ophthalmic manifestations and associated systemic disorders. Br J Ophthalmol 1993; 77:358.</a></li><li><a class="nounderline abstract_t">Gregg N. Congenital cataract following German measles in the mother. Trans Ophthalmol Soc Austr 1941; 3:35.</a></li><li><a class="nounderline abstract_t">GREGG NM. Congenital defects associated with maternal rubella. Aust Hosp 1947; 14:7.</a></li><li><a class="nounderline abstract_t">Cooper LZ, Krugman S. Clinical manifestations of postnatal and congenital rubella. Arch Ophthalmol 1967; 77:434.</a></li><li><a class="nounderline abstract_t">Cradock-Watson JE, Ridehalgh MK, Anderson MJ, et al. Fetal infection resulting from maternal rubella after the first trimester of pregnancy. J Hyg (Lond) 1980; 85:381.</a></li><li><a class="nounderline abstract_t">Peckham C. Congenital rubella in the United Kingdom before 1970: the prevaccine era. Rev Infect Dis 1985; 7 Suppl 1:S11.</a></li><li><a class="nounderline abstract_t">Grillner L, Forsgren M, Barr B, et al. Outcome of rubella during pregnancy with special reference to the 17th-24th weeks of gestation. Scand J Infect Dis 1983; 15:321.</a></li><li><a class="nounderline abstract_t">Enders G, Nickerl-Pacher U, Miller E, Cradock-Watson JE. Outcome of confirmed periconceptional maternal rubella. Lancet 1988; 1:1445.</a></li><li class="breakAll">Schiff GM, Sutherland J, Light I. Congenital rubella. In: Prenatal Infections. International Symposium of Vienna, Thalhammer O (Ed), Georg Thieme Verlag, Stuttgart 1971. p.31.</li><li><a class="nounderline abstract_t">Forrest JM, Turnbull FM, Sholler GF, et al. Gregg's congenital rubella patients 60 years later. Med J Aust 2002; 177:664.</a></li><li><a class="nounderline abstract_t">McIntosh ED, Menser MA. A fifty-year follow-up of congenital rubella. Lancet 1992; 340:414.</a></li><li><a class="nounderline abstract_t">Menser MA, Dods L, Harley JD. A twenty-five-year follow-up of congenital rubella. Lancet 1967; 2:1347.</a></li><li><a class="nounderline abstract_t">Toizumi M, Vo HM, Dang DA, et al. Clinical manifestations of congenital rubella syndrome: A review of our experience in Vietnam. Vaccine 2019; 37:202.</a></li><li><a class="nounderline abstract_t">Cooper LZ, Ziring PR, Ockerse AB, et al. Rubella. Clinical manifestations and management. Am J Dis Child 1969; 118:18.</a></li><li><a class="nounderline abstract_t">Oster ME, Riehle-Colarusso T, Correa A. An update on cardiovascular malformations in congenital rubella syndrome. Birth Defects Res A Clin Mol Teratol 2010; 88:1.</a></li><li><a class="nounderline abstract_t">Sever JL, South MA, Shaver KA. Delayed manifestations of congenital rubella. Rev Infect Dis 1985; 7 Suppl 1:S164.</a></li><li><a class="nounderline abstract_t">Fortuin NJ, Morrow AG, Roberts WC. Late vascular manifestations of the rubella syndrome. A roentgenographic-pathologic study. Am J Med 1971; 51:134.</a></li><li><a class="nounderline abstract_t">Desmond MM, Fisher ES, Vorderman AL, et al. The longitudinal course of congenital rubella encephalitis in nonretarded children. J Pediatr 1978; 93:584.</a></li><li><a class="nounderline abstract_t">Anderson H, Barr B, Wedenberg E. Genetic disposition--a prerequisite for maternal rubella deafness. Arch Otolaryngol 1970; 91:141.</a></li><li><a class="nounderline abstract_t">Shaver KA, Boughman JA, Nance WE. Congenital rubella syndrome and diabetes: a review of epidemiologic, genetic, and immunologic factors. Am Ann Deaf 1985; 130:526.</a></li><li><a class="nounderline abstract_t">Fine PE, Adelstein AM, Snowman J, et al. Long term effects of exposure to viral infections in utero. Br Med J (Clin Res Ed) 1985; 290:509.</a></li><li><a class="nounderline abstract_t">Takasu N, Ikema T, Komiya I, Mimura G. Forty-year observation of 280 Japanese patients with congenital rubella syndrome. Diabetes Care 2005; 28:2331.</a></li><li><a class="nounderline abstract_t">AvRuskin TW, Brakin M, Juan C. Congenital rubella and myxedema. Pediatrics 1982; 69:495.</a></li><li><a class="nounderline abstract_t">Ziring PR, Fedun BA, Cooper LZ. Letter: Thyrotoxicosis in congenital rubella. J Pediatr 1975; 87:1002.</a></li><li><a class="nounderline abstract_t">Ziring PR, Gallo G, Finegold M, et al. Chronic lymphocytic thyroiditis: identification of rubella virus antigen in the thyroid of a child with congenital rubella. J Pediatr 1977; 90:419.</a></li><li><a class="nounderline abstract_t">Nieburg PI, Gardner LI. Letter: Thyroiditis and congenital rubella syndrome. J Pediatr 1976; 89:156.</a></li><li><a class="nounderline abstract_t">Comas AP. Letter: Congenital rubella and acquired hypothyroidism secondary to Hashimoto thyroiditis. J Pediatr 1976; 88:1065.</a></li><li><a class="nounderline abstract_t">Preece MA, Kearney PJ, Marshall WC. Growth-hormone deficiency in congenital rubella. Lancet 1977; 2:842.</a></li><li><a class="nounderline abstract_t">Duszak RS. Congenital rubella syndrome--major review. Optometry 2009; 80:36.</a></li><li><a class="nounderline abstract_t">O'Neill JF. The ocular manifestations of congenital infection: a study of the early effect and long-term outcome of maternally transmitted rubella and toxoplasmosis. Trans Am Ophthalmol Soc 1998; 96:813.</a></li><li><a class="nounderline abstract_t">Weil ML, Itabashi H, Cremer NE, et al. Chronic progressive panencephalitis due to rubella virus simulating subacute sclerosing panencephalitis. N Engl J Med 1975; 292:994.</a></li><li><a class="nounderline abstract_t">Townsend JJ, Baringer JR, Wolinsky JS, et al. Progressive rubella panencephalitis. Late onset after congenital rubella. N Engl J Med 1975; 292:990.</a></li><li><a class="nounderline abstract_t">Ameratunga R, Woon ST, Koopmans W, French J. Cellular and molecular characterisation of the hyper immunoglobulin M syndrome associated with congenital rubella infection. J Clin Immunol 2009; 29:99.</a></li><li><a class="nounderline abstract_t">Palacin PS, Castilla Y, Garzón P, et al. Congenital rubella syndrome, hyper-IgM syndrome and autoimmunity in an 18-year-old girl. J Paediatr Child Health 2007; 43:716.</a></li><li><a class="nounderline abstract_t">Plotkin SA, Cochran W, Lindquist JM, et al. Congenital rubella syndrome in late infancy. JAMA 1967; 200:435.</a></li><li><a class="nounderline abstract_t">Cooper LZ, Krugman S. Diagnosis and management: congenital rubella. Pediatrics 1966; 37:335.</a></li><li><a class="nounderline abstract_t">Lindquist JM, Plotkin SA, Shaw L, et al. Congenital rubella syndrome as a systemic infection. Studies of affected infants born in Philadelphia, U.S.A. Br Med J 1965; 2:1401.</a></li><li><a class="nounderline abstract_t">Shewmon DA, Cherry JD, Kirby SE. Shedding of rubella virus in a 4 1/2-year-old boy with congenital rubella. Pediatr Infect Dis 1982; 1:342.</a></li><li><a class="nounderline abstract_t">Rawls WE, Phillips A, Melnick JL, Desmond MM. Persistent virus infection in congenital rubella. Arch Ophthalmol 1967; 77:430.</a></li><li><a class="nounderline abstract_t">Menser MA, Harley JD, Hertzberg R, et al. Persistence of virus in lens for three years after prenatal rubella. Lancet 1967; 2:387.</a></li><li><a class="nounderline abstract_t">PHILLIPS CA, MELNICK JL, YOW MD, et al. PERSISTENCE OF VIRUS IN INFANTS WITH CONGENITAL RUBELLA AND IN NORMAL INFANTS WITH A HISTORY OF MATERNAL RUBELLA. JAMA 1965; 193:1027.</a></li><li><a class="nounderline abstract_t">Control and prevention of rubella: evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome. MMWR Recomm Rep 2001; 50:1.</a></li><li><a class="nounderline abstract_t">Nickerson JP, Richner B, Santy K, et al. Neuroimaging of pediatric intracranial infection--part 2: TORCH, viral, fungal, and parasitic infections. J Neuroimaging 2012; 22:e52.</a></li><li class="breakAll">CDC, Congenital Rubella Syndrome (CRS) 2010 Case Definition, available at: https://ndc.services.cdc.gov/case-definitions/rubella-congenital-syndrome-2010/ (Accessed on May 10, 2023).</li><li class="breakAll">American Academy of Pediatrics. Rubella. In: Red Book: 2018 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Itasca, IL 2018. p.705.</li><li><a class="nounderline abstract_t">Dimech W, Panagiotopoulos L, Marler J, et al. Evaluation of three immunoassays used for detection of anti-rubella virus immunoglobulin M antibodies. Clin Diagn Lab Immunol 2005; 12:1104.</a></li><li class="breakAll">Lanzieri T, Redd S, Abernathy E, Icenogle J. Congenital Rubella Syndrome. In: Manual for the Surveillance of Vaccine-Preventable Diseases, Roush SW, Baldy LM, Hall MAK (Eds), Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Disease, 2020.</li><li><a class="nounderline abstract_t">O'Shea S, Best J, Banatvala JE. A lymphocyte transformation assay for the diagnosis of congenital rubella. J Virol Methods 1992; 37:139.</a></li><li><a class="nounderline abstract_t">Iuorio JL, Hosking CS, Pyman C. Retrospective diagnosis of congenital rubella. Br Med J (Clin Res Ed) 1984; 289:1566.</a></li><li><a class="nounderline abstract_t">Fuccillo DA, Steele RW, Hensen SA, et al. Impaired cellular immunity to rubella virus in congenital rubella. Infect Immun 1974; 9:81.</a></li><li><a class="nounderline abstract_t">Herne V, Hedman K, Reedik P. Immunoglobulin G avidity in the serodiagnosis of congenital rubella syndrome. Eur J Clin Microbiol Infect Dis 1997; 16:763.</a></li><li><a class="nounderline abstract_t">Thomas HI, Morgan-Capner P, Cradock-Watson JE, et al. Slow maturation of IgG1 avidity and persistence of specific IgM in congenital rubella: implications for diagnosis and immunopathology. J Med Virol 1993; 41:196.</a></li><li><a class="nounderline abstract_t">Hyde TB, Sato HK, Hao L, et al. Identification of Serologic Markers for School-Aged Children With Congenital Rubella Syndrome. J Infect Dis 2015; 212:57.</a></li><li><a class="nounderline abstract_t">Rajasundari TA, Sundaresan P, Vijayalakshmi P, et al. Laboratory confirmation of congenital rubella syndrome in infants: an eye hospital based investigation. J Med Virol 2008; 80:536.</a></li><li><a class="nounderline abstract_t">Revello MG, Baldanti F, Sarasini A, et al. Prenatal diagnosis of rubella virus infection by direct detection and semiquantitation of viral RNA in clinical samples by reverse transcription-PCR. J Clin Microbiol 1997; 35:708.</a></li><li><a class="nounderline abstract_t">Bosma TJ, Corbett KM, O'Shea S, et al. PCR for detection of rubella virus RNA in clinical samples. J Clin Microbiol 1995; 33:1075.</a></li><li><a class="nounderline abstract_t">Arvin AM, Schmidt NJ, Cantell K, Merigan TC. Alpha interferon administration to infants with congenital rubella. Antimicrob Agents Chemother 1982; 21:259.</a></li><li><a class="nounderline abstract_t">Larsson A, Forsgren M, Hård af Segerstad S, et al. Administration of interferon to an infant with congenital rubella syndrome involving persistent viremia and cutaneous vasculitis. Acta Paediatr Scand 1976; 65:105.</a></li><li class="breakAll">Cherry J, Demmler-Harrison GJ, Kaplan SL, et al. Rubella virus. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 8th ed, Elsevier, 2018. p.1601.</li><li><a class="nounderline abstract_t">Alford CA Jr, Kanich LS. Congenital rubella: a review of the virologic and serologic phenomena occurring after maternal rubella in the first trimester. South Med J 1966; 59:745.</a></li><li><a class="nounderline abstract_t">American Academy of Pediatrics, Joint Committee on Infant Hearing. Year 2007 position statement: Principles and guidelines for early hearing detection and intervention programs. Pediatrics 2007; 120:898.</a></li><li><a class="nounderline abstract_t">Harlor AD Jr, Bower C, Committee on Practice and Ambulatory Medicine, Section on Otolaryngology-Head and Neck Surgery. Hearing assessment in infants and children: recommendations beyond neonatal screening. Pediatrics 2009; 124:1252.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Rubella. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book, 12th ed, Atkinson W, Wolfe S, Hamborsky J (Eds). Public Health Foundation, Washington, DC 2011. http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/rubella.pdf (Accessed on August 10, 2011).</li><li><a class="nounderline abstract_t">Rubella prevention. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1990; 39(RR-15):1.</a></li><li class="breakAll">American Academy of Pediatrics. Rubella. In: Red Book: 2018-2021 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW, Long SS, Brady MT, et al (Eds), American Academy of Pediatrics, 2018. p.705.</li><li><a class="nounderline abstract_t">Al Hammoud R, Murphy JR, Pérez N. Imported Congenital Rubella Syndrome, United States, 2017. Emerg Infect Dis 2018; 24:800.</a></li><li><a class="nounderline abstract_t">Baltimore RS, Nimkin K, Sparger KA, et al. Case 4-2018: A Newborn with Thrombocytopenia, Cataracts, and Hepatosplenomegaly. N Engl J Med 2018; 378:564.</a></li></ol></div><div id="topicVersionRevision">Topic 6047 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10913402" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Preparing for elimination of congenital Rubella syndrome (CRS): summary of a workshop on CRS elimination in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15788995" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Elimination of rubella and congenital rubella syndrome--United States, 1969-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18971920" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Progress toward elimination of rubella and congenital rubella syndrome--the Americas, 2003-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15729220" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Progress toward elimination of measles and prevention of congenital rubella infection--European region, 1990-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35143468" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Progress Toward Rubella and Congenital Rubella Syndrome Control and Elimination - Worldwide, 2012-2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25990237" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The Americas region declares that rubella has been eliminated.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25990237" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The Americas region declares that rubella has been eliminated.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9699240" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Teratogen update: congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5327057" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Immunofluorescent studies on rubella-infected tissue cultures and human tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4304589" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Congenital rubella: the significance of virus persistence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6018109" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cerebral lesions in congenital rubella syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6126663" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Consequences of confirmed maternal rubella at successive stages of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3890105" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The history and medical consequences of rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5898080" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pathogenesis of congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11023958" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Rubella virus replication and links to teratogenicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14246083" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : THE IN VITRO GROWTH OF RUBELLA VIRUS IN HUMAN EMBRYO CELLS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5600965" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Metabolism of rubella virus-infected BHK 21 cells. Enhanced glycolysis and late cellular inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6023662" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Human fibroblasts infected with rubella virus produce a growth inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10049827" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Rubella virus-induced apoptosis varies among cell lines and is modulated by Bcl-XL and caspase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15018665" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Rubella virus does not induce apoptosis in primary human embryo fibroblast cultures: a possible way of viral persistence in congenital infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17920097" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Analysis of gene expression in fetal and adult cells infected with rubella virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15064032" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/386238" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Impaired cell-mediated immune response in patients with congenital rubella: correlation with gestational age at time of infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8345195" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Selective tolerance to the E1 protein of rubella virus in congenital rubella syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8345195" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Selective tolerance to the E1 protein of rubella virus in congenital rubella syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1107411" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Specific immunoglobulins in infants with the congenital rubella syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5046774" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical and laboratory study of children exposed in utero to maternal rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5129528" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Loss of rubella hemagglutination inhibition antibody in congenital rubella. Failure of seronegative children with congenital rubella to respond to HPV-77 rubella vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4170270" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Immunoglobulins and rubella-virus antibodies in adults with congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4183537" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Declining antibody titers in children with congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4183537" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Declining antibody titers in children with congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5926471" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hypogammaglobulinemia in an infant with congenital rubella syndrome; failure of 1-adamantanamine to stop irus excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6859910" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The nerve deaf child--intrauterine rubella or not?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9093941" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The role of rubella-immunoblot and rubella-peptide-EIA for the diagnosis of the congenital rubella syndrome during the prenatal and newborn periods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2938855" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Late-onset rubella syndrome: coexistence of immune complex disease and defective cytotoxic effector cell function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3490785" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Congenital rubella. Monoclonal antibody-defined T cell abnormalities in young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6049075" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Phytohaemagglutinin unresponsiveness of lymphocytes from babies with congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6049075" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Phytohaemagglutinin unresponsiveness of lymphocytes from babies with congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3890104" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Diabetes mellitus and autoimmunity in patients with the congenital rubella syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12930364" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Humoral beta-cell autoimmunity is rare in patients with the congenital rubella syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18641967" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Congenital rubella: citation virus or viral cause of type 1 diabetes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6959935" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The HLA system in congenital rubella patients with and without diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/74564" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Rubella infection and diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12378375" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The role of viruses in human diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10439311" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : CD4+ and CD8+ T-cell clones from congenital rubella syndrome patients with IDDM recognize overlapping GAD65 protein epitopes. Implications for HLA class I and II allelic linkage to disease susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8318483" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Congenital rubella syndrome: ophthalmic manifestations and associated systemic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Congenital cataract following German measles in the mother</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18914301" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Congenital defects associated with maternal rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4164540" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical manifestations of postnatal and congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7462590" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Fetal infection resulting from maternal rubella after the first trimester of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4001719" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Congenital rubella in the United Kingdom before 1970: the prevaccine era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6658380" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Outcome of rubella during pregnancy with special reference to the 17th-24th weeks of gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2898593" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Outcome of confirmed periconceptional maternal rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2898593" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Outcome of confirmed periconceptional maternal rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12463994" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Gregg's congenital rubella patients 60 years later.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1353568" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A fifty-year follow-up of congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4170037" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A twenty-five-year follow-up of congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30503658" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinical manifestations of congenital rubella syndrome: A review of our experience in Vietnam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5815335" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Rubella. Clinical manifestations and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19697432" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : An update on cardiovascular malformations in congenital rubella syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4001724" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Delayed manifestations of congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5570316" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Late vascular manifestations of the rubella syndrome. A roentgenographic-pathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/81297" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The longitudinal course of congenital rubella encephalitis in nonretarded children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4983006" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Genetic disposition--a prerequisite for maternal rubella deafness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3832941" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Congenital rubella syndrome and diabetes: a review of epidemiologic, genetic, and immunologic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3918651" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Long term effects of exposure to viral infections in utero.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16123517" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Forty-year observation of 280 Japanese patients with congenital rubella syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7070899" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Congenital rubella and myxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1185372" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Letter: Thyrotoxicosis in congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/576429" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Chronic lymphocytic thyroiditis: identification of rubella virus antigen in the thyroid of a child with congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/932887" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Letter: Thyroiditis and congenital rubella syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/946816" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Letter: Congenital rubella and acquired hypothyroidism secondary to Hashimoto thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/72194" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Growth-hormone deficiency in congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19111256" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Congenital rubella syndrome--major review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10360309" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The ocular manifestations of congenital infection: a study of the early effect and long-term outcome of maternally transmitted rubella and toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/47149" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Chronic progressive panencephalitis due to rubella virus simulating subacute sclerosing panencephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1117960" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Progressive rubella panencephalitis. Late onset after congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18663564" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Cellular and molecular characterisation of the hyper immunoglobulin M syndrome associated with congenital rubella infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17854460" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Congenital rubella syndrome, hyper-IgM syndrome and autoimmunity in an 18-year-old girl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4164423" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Congenital rubella syndrome in late infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5948130" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Diagnosis and management: congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5892115" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Congenital rubella syndrome as a systemic infection. Studies of affected infants born in Philadelphia, U.S.A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7155967" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Shedding of rubella virus in a 4 1/2-year-old boy with congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6022715" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Persistent virus infection in congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4166332" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Persistence of virus in lens for three years after prenatal rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14338802" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : PERSISTENCE OF VIRUS IN INFANTS WITH CONGENITAL RUBELLA AND IN NORMAL INFANTS WITH A HISTORY OF MATERNAL RUBELLA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11475328" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Control and prevention of rubella: evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22309611" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Neuroimaging of pediatric intracranial infection--part 2: TORCH, viral, fungal, and parasitic infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22309611" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Neuroimaging of pediatric intracranial infection--part 2: TORCH, viral, fungal, and parasitic infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22309611" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Neuroimaging of pediatric intracranial infection--part 2: TORCH, viral, fungal, and parasitic infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16148178" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Evaluation of three immunoassays used for detection of anti-rubella virus immunoglobulin M antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16148178" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Evaluation of three immunoassays used for detection of anti-rubella virus immunoglobulin M antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1597504" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A lymphocyte transformation assay for the diagnosis of congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6439320" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Retrospective diagnosis of congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4808855" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Impaired cellular immunity to rubella virus in congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9405951" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Immunoglobulin G avidity in the serodiagnosis of congenital rubella syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8263500" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Slow maturation of IgG1 avidity and persistence of specific IgM in congenital rubella: implications for diagnosis and immunopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25362195" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Identification of Serologic Markers for School-Aged Children With Congenital Rubella Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18205220" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Laboratory confirmation of congenital rubella syndrome in infants: an eye hospital based investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9041417" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Prenatal diagnosis of rubella virus infection by direct detection and semiquantitation of viral RNA in clinical samples by reverse transcription-PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7615708" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : PCR for detection of rubella virus RNA in clinical samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6176183" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Alpha interferon administration to infants with congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1251716" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Administration of interferon to an infant with congenital rubella syndrome involving persistent viremia and cutaneous vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1251716" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Administration of interferon to an infant with congenital rubella syndrome involving persistent viremia and cutaneous vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5949027" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Congenital rubella: a review of the virologic and serologic phenomena occurring after maternal rubella in the first trimester.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17908777" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Year 2007 position statement: Principles and guidelines for early hearing detection and intervention programs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19786460" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Hearing assessment in infants and children: recommendations beyond neonatal screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19786460" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Hearing assessment in infants and children: recommendations beyond neonatal screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Recommendations of the Immunization Practices Advisory Committee (ACIP)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Recommendations of the Immunization Practices Advisory Committee (ACIP)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29553333" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Imported Congenital Rubella Syndrome, United States, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29414276" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Case 4-2018: A Newborn with Thrombocytopenia, Cataracts, and Hepatosplenomegaly.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
